|
Synonyms: clone OGD1.0.0 [2] | PF-06252616 | PF06252616
Compound class:
Antibody
Comment: Domagrozumab is a humanized monoclonal antibody targeting myostatin (MSTN), being investigated for potential therapeutic action in muscle wasting diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with sequences claimed in patent US8992913 [2]. |
| No information available. |
Summary of Clinical Use  |
| Domagrozumab is being evaluated in a Phase 2 safety, efficacy, pharmacokinetics and pharmacodynamics clinical trial in patients suffering from Duchenne muscular dystrophy (NCT02310763). |
| Mechanism Of Action and Pharmacodynamic Effects |
| In normal physiology myostatin (also known as growth differentiation factor 8, abbreviated GDF-8) is an autocrine myokine that acts on muscle cells to inhibit myogenesis i.e. muscle cell growth and differentiation. Inhibition of myostatin improves muscle histology, mass, and function. It is hypothesised that myostatin inhibitors may slow disease progression in DMD by delaying fibrotic infiltration in dystrophic muscle [1] as well as potentially increasing myocyte growth and differentiation. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02310763 | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy | Phase 2 Interventional | Pfizer | ||
